Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Surprising Drug Blocks Malaria
Uncategorized

Surprising Drug Blocks Malaria

By medwebJan 1, 2007
Share
Facebook Twitter Email

January 15, 2007

Contact: Marla Paul at (312) 503-8928 or at
marla-paul@northwestern.edu

Surprising Drug Blocks Malaria

CHICAGO—Northwestern University researchers have discovered how malaria parasites persuade red blood cells to engulf them—and how to block the invading parasites. The malaria marauders hack into the red cell’s signaling system and steal the molecular equivalent of its password to spring open the door to the cell. But researchers have found that a common blood pressure medication—propranolol—jams the signal to prevent the parasite from breaking in.

Scientists had long been perplexed by malaria’s ability to hijack red blood cells, then wildly multiply and provoke the life-threatening symptoms of malaria.

“This opens the possibility for important new drugs for malaria that won’t become resistant. New drugs are urgently needed because the parasite has evolved resistance against virtually all types of commonly used drugs,” said Kasturi Haldar, PhD, principal investigator for the study and Charles E. and Emma H. Morrison Professor of Pathology at Northwestern’s Feinberg School of Medicine. Sean Murphy, a Medical Scientist Training Program student, is the study’s lead author.

The study was published in PLoS Medicine.

Malaria, one of the top three deadliest diseases in the developing world, is resurging worldwide because of drug resistance and the lack of an effective vaccine, Dr. Haldar said. Jamaica recently reported an outbreak of malaria after it had been eradicated in that country for 50 years.

A blood-borne illness, malaria is transmitted by infected mosquitoes. The symptoms include high fevers and flu-like symptoms such as chills, headache, muscle aches, and fatigue. The disease kills an estimated 2 million people a year, mostly African children under age five. It also poses a risk to travelers. An estimated 500 million cases of malaria were expected in 2006.

Commonly used drugs against malaria attack the parasite, but it rapidly changes its molecular structure to become resistant to those drugs. It would be difficult, however, for the malaria parasite to develop resistance to a drug that acts on a person’s red blood cells as the blood pressure medication does, Dr. Haldar said.

When Dr. Haldar and her colleagues tested propranolol in combination with existing antimalarial drugs in human cell cultures and mice, it reduced the dose of the antimalarial drugs needed to kill the parasites by tenfold. That’s significant because high doses of antimalarial drugs—increasingly necessary as resistance to them builds—can be toxic. In addition, blood pressure medication like propranolol is cheap and safe for use even in pregnant women, a group particularly vulnerable to malaria.

“We’re working on developing a unique drug that would combine antimalarial drugs with blood pressure medication. We think it has a high likelihood of success,” Dr. Haldar said. The next step is human clinical trials.

The study was funded by an American Heart Association fellowship, a Northwestern University presidential fellowship, and National Institutes of Health grants.

To read the PLoS article visit http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371%2Fjournal.pmed.0030528

Share. Facebook Twitter Email

Related Posts

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Rewriting the Role of a Transcription Factor

Mar 19, 2020

Comments are closed.

Latest News

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642
20230317_NM643
20230317_NM624
20230317_NM303
20230317_NM551
20230317_NM559
20230317_NM536
20230317_NM508

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.